科研之友
微信
新浪微博
Facebook
分享链接
摘要
Specific molecular probes are essential for the early diagnosis of prostate cancer. In addition, peptides have been shown to have numerous uses as diagnostic and therapeutic molecular probes. The K237 peptide binds to the vascular endothelial growth factor receptor with high affinity and specificity, and was predicted to have potential use as a probe in tumor angiogenesis. The overall aim of the present study was to assess the diagnostic potential of I-131-K237 as a molecular probe for prostate cancer. The K237 peptide was radiolabeled with I-131 using an Iodogen method. The radiolabeling efficiency and radiochemical purity were found to be 73.7 +/- 3.2 and 96.7 +/- 0.6%, respectively, which were determined using thin layer chromatography and high performance liquid chromatography in vitro. Cellular uptake and competition binding experiments were used to identify the affinity of I-131-K237 to LNCaP prostate cancer cells. The binding ratio of I-131-K237 to LNCaP cells in the experimental group was 95.8 +/- 1.5%, whereas the binding ratios in the 5 kBq (NaI)-I-131, 10 kBq (NaI)-I-131, 15 kBq (NaI)-I-131 and PBS groups were 8.2 +/- 0.4, 8.3 +/- 0.2, 8.5 +/- 0.2 and 0.0%, respectively. In addition, the binding ratio of I-131-K237 to LNCaP significantly decreased with the increased dose of unlabeled K237. A total of 40 male BALB/c mice with LNCaP xenografts were used for biodistribution and single photon emission computed tomography imaging analysis. An image was obtained and tumors were visible from 2 h post injection of I-131-K237. In conclusion, the results of the present study showed that I-131-K237 had a high affinity for LNCaP cells and may be considered as a candidate diagnostic molecular probe for prostate cancer.
